Announcements Trials

Browse Landscape

Phase

Status

Completed 35 Terminated 16 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Medullary 1

Interventions

pembrolizumab 85 Specimen Handling 78 Carboplatin 73 Magnetic Resonance Spectroscopy 70 Biopsy 58 Nivolumab 55 Cisplatin 54 Paclitaxel 46 Cyclophosphamide 45 durvalumab 37 Radiotherapy 37 Radiation 36 olaparib 34 Rituximab 34 Etoposide 34 Dexamethasone 33 Ipilimumab 30 Gemcitabine 30 Doxorubicin 29 Lenalidomide 28 Taxes 27 Docetaxel 27 Pemetrexed 25 Bevacizumab 24 Prednisone 23 Cytarabine 23 X-Rays 22 Vincristine 21 Trastuzumab 21 cabozantinib 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Has results × vandetanib × Clear all

NCT04211337 2026-03-19

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting

291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡